Literature DB >> 15389811

Androgen deprivation therapy for prostate cancer: current status and future prospects.

Hiroshi Miyamoto1, Edward M Messing, Chawnshang Chang.   

Abstract

Androgens play a major role in promoting the development and progression of prostate cancer. As a result, androgen ablation or blockade of androgen action through the androgen receptor (AR) has been the cornerstone of treatment of advanced prostate cancer. Different strategies involving this hormonal therapy produce a significant clinical response in most of the patients, but most responders eventually lose dependency, resulting in mortality. Thus, whether hormonal therapy contributes to the improvement of overall survival rates, especially in patients with advanced prostate cancer, remains controversial. However, patients with advanced disease clearly have a benefit from androgen deprivation-based treatment for palliating their symptoms and for improving the quality of their lives. In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15389811     DOI: 10.1002/pros.20115

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  103 in total

1.  Comparison of maximal and more maximal intermittent androgen blockade during 5-year treatment of advanced prostate cancer T3NxMx-1.

Authors:  Slawomir A Dutkiewicz
Journal:  Int Urol Nephrol       Date:  2011-09-20       Impact factor: 2.370

2.  Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Authors:  David J Degraff; Adam A Aguiar; Qian Chen; Lisa K Adams; B Jill Williams; Robert A Sikes
Journal:  Am J Transl Res       Date:  2010-03-06       Impact factor: 4.060

3.  Androgen and its receptor promote Bax-mediated apoptosis.

Authors:  Yuting Lin; John Kokontis; Fangming Tang; Bradley Godfrey; Shutsung Liao; Anning Lin; Youting Chen; Jialing Xiang
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Androgen modulation of coregulator expression in prostate cancer cells.

Authors:  Hannelore V Heemers; Kevin M Regan; Lucy J Schmidt; S Keith Anderson; Karla V Ballman; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2009-01-22

5.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Authors:  Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

Review 6.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

7.  C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction.

Authors:  J Zhang; M Gonit; M D Salazar; A Shatnawi; L Shemshedini; R Trumbly; M Ratnam
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

8.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

9.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

10.  Malignant phenotype of PC3 cell line was inhibited by siRNA targeting PAR gene.

Authors:  Xiaofeng Xu; Siwei Zhou; Zhengyu Zhang; Jingping Ge; Wen Cheng; Zhifeng Wei; Xu Zhang; Jianping Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.